Although the underlying mechanisms of these theories have not been resolved, it has been proposed that the clinical efficacy of HER2 blockade in tumors classified as HER2-neg might be explained by the “cancer stem cell hypothesis” where cancers, including BC, are driven by a subpopulation of cells that display stem cell properties [39]. The gene discussed is ERBB2; the disease is breast cancer.